

**Faron Pharmaceuticals Oy**

("Faron" or the "Company")

**Faron to Present at Canaccord Horizons in Oncology Virtual Conference**

*Press release, April 13, 2023*

**TURKU, FINLAND / BOSTON, MA** - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling cancers via immunotherapy, today announces that Chief Executive Officer, Dr. Markku Jalkanen and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20 at 8 AM EST.

Faron will present on the panel, "Boosting checkpoint inhibitors – finally two solutions?". Dr. Jalkanen and Dr. Fjällskog will discuss the most recent data for *bexmarilimab*, the company's wholly owned immunotherapy asset, for treating hematological malignancies and solid tumors.

**For more information please contact:**

**Investor Contact**

**Faron Pharmaceuticals**

Julia Balanova

VP, Investor Relations

[julia.balanova@faron.com](mailto:julia.balanova@faron.com)

[investor.relations@faron.com](mailto:investor.relations@faron.com)

Phone: +1 (917) 306-6096

**Media Contact**

**Faron Pharmaceuticals**

Jennifer C. Smith-Parker

Head of Communications

[Jennifer.Smith-Parker@faron.com](mailto:Jennifer.Smith-Parker@faron.com)

**Cairn Financial Advisers LLP, Nomad**

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

**Peel Hunt LLP, Broker**

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

**Sisu Partners Oy, Certified Adviser on Nasdaq First North**

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

**Consilium Strategic Communications**

Mary-Jane Elliott, David Daley, Lindsey Neville

[faron@consilium-comms.com](mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

**About Bexmarilimab**

*Bexmarilimab* is Faron's wholly owned, investigational immunotherapy with the potential to provide immune stimulation for treatment-resistant cancers through targeting myeloid cell function. A novel anti-CLEVER-1 humanised antibody, *bexmarilimab* targets CLEVER-1 positive (Common Lymphatic Endothelial and Vascular Endothelial Receptor 1) tumor-associated macrophages (TAMs) in the tumor microenvironment, converting highly immunosuppressive M2 macrophages to immune-stimulating M1 macrophages. As an immunology therapy, *bexmarilimab* has therapeutic potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules in both solid tumors and hematologic malignancies.

**About Faron Pharmaceuticals Oy**

Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) together with its subsidiaries, is a clinical stage biopharmaceutical group focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation. *Bexmarilimab*, a novel anti-CLEVER-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with hematological cancers and untreatable solid tumors, *bexmarilimab* has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. In terms of other pipeline assets, Traumakine® is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of hyperinflammatory conditions. Faron is headquartered in Turku, Finland. Further information is available at [www.faron.com](http://www.faron.com).